查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1861366

琥珀酸夫羅曲坦錠：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Frovatriptan Succinate Tablets - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 122 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球琥珀酸夫羅曲坦片劑市場規模估計為 3,115 萬美元，預計到 2031 年將成長至 3,955 萬美元，2025 年至 2031 年的複合年成長率為 3.5%。

本報告全面評估了跨境產業佈局、資本配置模式、區域經濟相互依存關係以及供應鏈重組與近期關稅調整和國際對琥珀酸夫羅曲坦片採取的戰略反制措施之間的關係。

琥珀酸夫羅曲坦錠是一種選擇性5-HT1B/1D受體促效劑，主要用於治療急性偏頭痛發作。其上游供應鏈涉及高純度活性藥物原料藥（API）和化學中間體的合成，這些成分主要來自歐洲和印度的專業API生產商。乳糖、澱粉和微晶纖維素等藥用輔料則由全球主要的輔料供應商提供。

下游客戶主要包括神經科、頭痛診所、零售藥局和線上處方平台。隨著偏頭痛患者數量的增加以及對有效治療方法需求的成長，琥珀酸夫羅曲坦錠在歐洲、美洲和亞洲市場的需求均穩定成長。未來，隨著個人化醫療和遠端醫療醫療處方服務的興起，該藥物在全球醫療保健領域的應用範圍有望進一步擴大。

預計到 2024 年，琥珀酸夫羅曲坦錠的全球平均價格約為每片 3.74 美元，總銷售量將達到約 833 萬片。

目前，琥珀酸夫羅曲坦錠的全球市場呈現兩極化的格局，既有品牌藥也有非專利藥，已發展成為曲坦類偏頭痛藥物中一個成熟的區隔市場。在美國和歐洲等已開發市場，受臨床指引推薦和廣泛醫保覆蓋的推動，市場需求保持穩定。同時，由於本土非專利生產商的進入，提高了藥物的可及性和可負擔性，亞太地區（尤其是中國和印度）的市場滲透率正在加速成長。整體而言，市場競爭主要體現在價格策略和分銷網路的擴張。

從生產角度來看，琥珀酸夫羅曲坦錠劑的生產需要高度精確的配方製程。常用輔料包括一水乳糖、微晶纖維素、膠體二氧化矽、羧甲基澱粉鈉、硬脂酸鎂和專用薄膜預混合料。這些輔料對於確保藥物的穩定性、生物利用度和患者依從性至關重要，凸顯了嚴格的品管和遵守現行藥品生產規範 (CGMP) 標準的重要性。 Endo Pharmaceuticals、Menarini、Ingenus Pharmaceutical 和 Glenmark 等公司擁有先進的生產設施和完善的品管體系，以確保穩定的供應和符合法規要求。原料供應鏈分為原料藥(API) 和輔料兩部分，每部分都需要經過嚴格的藥典測試，這給擴大生產規模和實現全球分銷帶來了複雜的挑戰。

展望未來，市場預計將保持相對穩定並實現溫和成長。一方面，由於偏頭痛盛行率上升以及新興市場診斷和治療率的提高，市場需求預計將保持穩定。另一方面，CGRP單株抗體和口服CGRP拮抗劑等新型治療方法的引入，對傳統曲坦類藥物構成了替代壓力。雖然夫羅曲坦及其相關藥物在成熟市場的市場佔有率可能會逐漸下降，但在醫療覆蓋範圍有限且對成本較為敏感的地區，預計它們仍將保持強勁的市場地位。主要成長要素包括臨床指引中對曲坦類藥物的持續採納、全球偏頭痛負擔的加重以及學名藥的成本優勢。然而，市場也面臨許多挑戰，包括來自新興治療領域的競爭威脅、嚴格的定價和處方法規結構，以及與副作用和聯合治療需求相關的患者依從性問題。這些趨勢共同塑造未來的市場機會和競爭格局。

本報告旨在對全球琥珀酸夫羅曲坦片市場依地區/國家、類型和應用進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售量（千片）和收入（百萬美元）為單位，對琥珀酸夫羅曲坦片市場規模、估算和預測進行了呈現，基準年為2024年，並涵蓋了2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定琥珀酸夫羅曲坦的業務/成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Endo International
  • Menarini
  • Ingenus Pharmaceutical
  • Glenmark Pharmaceuticals
  • SK Chemicals
  • Teva
  • GL Pharma
  • Clydesdale Pharma
  • Amneal Pharmaceuticals
  • Renata PLC
  • Qingdao Guoxin Pharmaceutical

依類型分類的區隔市場

  • 原藥
  • 學名藥

應用領域

  • 醫院和診所
  • 零售藥房
  • 其他

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Frovatriptan Succinate Tablets was estimated to be worth US$ 31.15 million in 2024 and is forecast to a readjusted size of US$ 39.55 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Frovatriptan Succinate Tablets cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Frovatriptan Succinate Tablets are selective 5-HT1B/1D receptor agonists, primarily indicated for the treatment of acute migraine attacks. The upstream supply chain involves the synthesis of high-purity active pharmaceutical ingredients (APIs) and chemical intermediates, largely supplied by specialized API manufacturers in Europe and India. Pharmaceutical excipients such as lactose, starch, and microcrystalline cellulose are provided by leading global excipient suppliers.

Downstream customers mainly include neurology departments, headache specialty clinics, retail pharmacies, and online prescription platforms. With the growing population of migraine patients and the increasing demand for effective treatment, Frovatriptan Succinate Tablets are experiencing steady demand growth in both Western and Asian markets. Looking ahead, the rise of personalized medicine and telemedicine prescription services is expected to expand the applications of this drug in the global healthcare landscape.

In 2024, the global average price of Frovatriptan Succinate Tablets is approximately USD 3.74 per tablet, with total sales reaching around 8.33 million tablets.

At present, the global market for Frovatriptan Succinate Tablets demonstrates a dual structure of originator and generic products, positioning it as a mature niche within the triptan class of migraine therapeutics. In developed markets such as the U.S. and Europe, demand remains steady due to clinical guideline endorsements and broad reimbursement coverage. Meanwhile, in Asia-Pacific, particularly China and India, market penetration is accelerating, supported by the entry of local generic manufacturers that enhance affordability and accessibility. Overall, competition is largely driven by pricing strategies and distribution expansion.

From a manufacturing perspective, the production of Frovatriptan Succinate Tablets involves high-precision formulation processes. Common excipients include lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, magnesium stearate, and specialized film-coating premixes. These excipients are critical for ensuring stability, bioavailability, and patient adherence, underscoring the importance of strict quality control and adherence to CGMP standards. Companies such as Endo Pharmaceuticals, Menarini, Ingenus Pharmaceutical, and Glenmark operate advanced facilities and robust quality management systems to ensure consistent supply and regulatory compliance. The raw material supply chain is divided into APIs and excipients, each subject to rigorous pharmacopoeia testing, highlighting the complexities inherent in scaling up production and enabling global distribution.

Looking ahead, the market is expected to remain relatively stable with modest growth. On one hand, the rising prevalence of migraine and improved diagnosis and treatment rates in emerging markets will sustain demand. On the other hand, the adoption of novel therapies such as CGRP monoclonal antibodies and oral CGRP antagonists is exerting substitution pressure on traditional triptans. While Frovatriptan and related agents may gradually lose share in mature markets, they are expected to retain a strong position in cost-sensitive regions with limited healthcare coverage. Key growth drivers include continued inclusion of triptans in clinical guidelines, the increasing global burden of migraine, and the cost advantage of generics. However, the market faces challenges such as competitive threats from new therapeutic classes, stringent regulatory frameworks on pricing and prescription, and patient adherence issues linked to side effects and the need for combination therapies. Together, these dynamics define the opportunities and competitive landscape of the future market.

This report aims to provide a comprehensive presentation of the global market for Frovatriptan Succinate Tablets, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Frovatriptan Succinate Tablets by region & country, by Type, and by Application.

The Frovatriptan Succinate Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Frovatriptan Succinate Tablets.

Market Segmentation

By Company

  • Endo International
  • Menarini
  • Ingenus Pharmaceutical
  • Glenmark Pharmaceuticals
  • SK Chemicals
  • Teva
  • G.L. Pharma
  • Clydesdale Pharma
  • Amneal Pharmaceuticals
  • Renata PLC
  • Qingdao Guoxin Pharmaceutical

Segment by Type

  • Original Drug
  • Generic Drug

Segment by Application

  • Hospital and Clinic
  • Retail Pharmacies
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Frovatriptan Succinate Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Frovatriptan Succinate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Frovatriptan Succinate Tablets in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Frovatriptan Succinate Tablets Product Introduction
  • 1.2 Global Frovatriptan Succinate Tablets Market Size Forecast
    • 1.2.1 Global Frovatriptan Succinate Tablets Sales Value (2020-2031)
    • 1.2.2 Global Frovatriptan Succinate Tablets Sales Volume (2020-2031)
    • 1.2.3 Global Frovatriptan Succinate Tablets Sales Price (2020-2031)
  • 1.3 Frovatriptan Succinate Tablets Market Trends & Drivers
    • 1.3.1 Frovatriptan Succinate Tablets Industry Trends
    • 1.3.2 Frovatriptan Succinate Tablets Market Drivers & Opportunity
    • 1.3.3 Frovatriptan Succinate Tablets Market Challenges
    • 1.3.4 Frovatriptan Succinate Tablets Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Frovatriptan Succinate Tablets Players Revenue Ranking (2024)
  • 2.2 Global Frovatriptan Succinate Tablets Revenue by Company (2020-2025)
  • 2.3 Global Frovatriptan Succinate Tablets Players Sales Volume Ranking (2024)
  • 2.4 Global Frovatriptan Succinate Tablets Sales Volume by Company Players (2020-2025)
  • 2.5 Global Frovatriptan Succinate Tablets Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Frovatriptan Succinate Tablets Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Frovatriptan Succinate Tablets Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Frovatriptan Succinate Tablets
  • 2.9 Frovatriptan Succinate Tablets Market Competitive Analysis
    • 2.9.1 Frovatriptan Succinate Tablets Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Frovatriptan Succinate Tablets Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Frovatriptan Succinate Tablets as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Original Drug
    • 3.1.2 Generic Drug
  • 3.2 Global Frovatriptan Succinate Tablets Sales Value by Type
    • 3.2.1 Global Frovatriptan Succinate Tablets Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Frovatriptan Succinate Tablets Sales Value, by Type (2020-2031)
    • 3.2.3 Global Frovatriptan Succinate Tablets Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Frovatriptan Succinate Tablets Sales Volume by Type
    • 3.3.1 Global Frovatriptan Succinate Tablets Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Frovatriptan Succinate Tablets Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Frovatriptan Succinate Tablets Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Frovatriptan Succinate Tablets Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital and Clinic
    • 4.1.2 Retail Pharmacies
    • 4.1.3 Other
  • 4.2 Global Frovatriptan Succinate Tablets Sales Value by Application
    • 4.2.1 Global Frovatriptan Succinate Tablets Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Frovatriptan Succinate Tablets Sales Value, by Application (2020-2031)
    • 4.2.3 Global Frovatriptan Succinate Tablets Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Frovatriptan Succinate Tablets Sales Volume by Application
    • 4.3.1 Global Frovatriptan Succinate Tablets Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Frovatriptan Succinate Tablets Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Frovatriptan Succinate Tablets Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Frovatriptan Succinate Tablets Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Frovatriptan Succinate Tablets Sales Value by Region
    • 5.1.1 Global Frovatriptan Succinate Tablets Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025)
    • 5.1.3 Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031)
    • 5.1.4 Global Frovatriptan Succinate Tablets Sales Value by Region (%), (2020-2031)
  • 5.2 Global Frovatriptan Succinate Tablets Sales Volume by Region
    • 5.2.1 Global Frovatriptan Succinate Tablets Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025)
    • 5.2.3 Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031)
    • 5.2.4 Global Frovatriptan Succinate Tablets Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Frovatriptan Succinate Tablets Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.4.2 North America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.5.2 Europe Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Frovatriptan Succinate Tablets Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.7.2 South America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.3.2 United States Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.4.2 Europe Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.5.2 China Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.6.2 Japan Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.7.2 South Korea Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.9.2 India Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Endo International
    • 7.1.1 Endo International Company Information
    • 7.1.2 Endo International Introduction and Business Overview
    • 7.1.3 Endo International Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Endo International Frovatriptan Succinate Tablets Product Offerings
    • 7.1.5 Endo International Recent Development
  • 7.2 Menarini
    • 7.2.1 Menarini Company Information
    • 7.2.2 Menarini Introduction and Business Overview
    • 7.2.3 Menarini Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Menarini Frovatriptan Succinate Tablets Product Offerings
    • 7.2.5 Menarini Recent Development
  • 7.3 Ingenus Pharmaceutical
    • 7.3.1 Ingenus Pharmaceutical Company Information
    • 7.3.2 Ingenus Pharmaceutical Introduction and Business Overview
    • 7.3.3 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
    • 7.3.5 Ingenus Pharmaceutical Recent Development
  • 7.4 Glenmark Pharmaceuticals
    • 7.4.1 Glenmark Pharmaceuticals Company Information
    • 7.4.2 Glenmark Pharmaceuticals Introduction and Business Overview
    • 7.4.3 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
    • 7.4.5 Glenmark Pharmaceuticals Recent Development
  • 7.5 SK Chemicals
    • 7.5.1 SK Chemicals Company Information
    • 7.5.2 SK Chemicals Introduction and Business Overview
    • 7.5.3 SK Chemicals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 SK Chemicals Frovatriptan Succinate Tablets Product Offerings
    • 7.5.5 SK Chemicals Recent Development
  • 7.6 Teva
    • 7.6.1 Teva Company Information
    • 7.6.2 Teva Introduction and Business Overview
    • 7.6.3 Teva Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Teva Frovatriptan Succinate Tablets Product Offerings
    • 7.6.5 Teva Recent Development
  • 7.7 G.L. Pharma
    • 7.7.1 G.L. Pharma Company Information
    • 7.7.2 G.L. Pharma Introduction and Business Overview
    • 7.7.3 G.L. Pharma Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 G.L. Pharma Frovatriptan Succinate Tablets Product Offerings
    • 7.7.5 G.L. Pharma Recent Development
  • 7.8 Clydesdale Pharma
    • 7.8.1 Clydesdale Pharma Company Information
    • 7.8.2 Clydesdale Pharma Introduction and Business Overview
    • 7.8.3 Clydesdale Pharma Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Clydesdale Pharma Frovatriptan Succinate Tablets Product Offerings
    • 7.8.5 Clydesdale Pharma Recent Development
  • 7.9 Amneal Pharmaceuticals
    • 7.9.1 Amneal Pharmaceuticals Company Information
    • 7.9.2 Amneal Pharmaceuticals Introduction and Business Overview
    • 7.9.3 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
    • 7.9.5 Amneal Pharmaceuticals Recent Development
  • 7.10 Renata PLC
    • 7.10.1 Renata PLC Company Information
    • 7.10.2 Renata PLC Introduction and Business Overview
    • 7.10.3 Renata PLC Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Renata PLC Frovatriptan Succinate Tablets Product Offerings
    • 7.10.5 Renata PLC Recent Development
  • 7.11 Qingdao Guoxin Pharmaceutical
    • 7.11.1 Qingdao Guoxin Pharmaceutical Company Information
    • 7.11.2 Qingdao Guoxin Pharmaceutical Introduction and Business Overview
    • 7.11.3 Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
    • 7.11.5 Qingdao Guoxin Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 Frovatriptan Succinate Tablets Industrial Chain
  • 8.2 Frovatriptan Succinate Tablets Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Frovatriptan Succinate Tablets Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Frovatriptan Succinate Tablets Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Frovatriptan Succinate Tablets Market Trends
  • Table 2. Frovatriptan Succinate Tablets Market Drivers & Opportunity
  • Table 3. Frovatriptan Succinate Tablets Market Challenges
  • Table 4. Frovatriptan Succinate Tablets Market Restraints
  • Table 5. Global Frovatriptan Succinate Tablets Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Frovatriptan Succinate Tablets Revenue Market Share by Company (2020-2025)
  • Table 7. Global Frovatriptan Succinate Tablets Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Frovatriptan Succinate Tablets Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Frovatriptan Succinate Tablets Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers Frovatriptan Succinate Tablets Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Frovatriptan Succinate Tablets Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Frovatriptan Succinate Tablets
  • Table 13. Global Frovatriptan Succinate Tablets Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Frovatriptan Succinate Tablets as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Frovatriptan Succinate Tablets Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Frovatriptan Succinate Tablets Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Frovatriptan Succinate Tablets Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Frovatriptan Succinate Tablets Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Frovatriptan Succinate Tablets Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Frovatriptan Succinate Tablets Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Frovatriptan Succinate Tablets Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global Frovatriptan Succinate Tablets Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global Frovatriptan Succinate Tablets Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Frovatriptan Succinate Tablets Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Frovatriptan Succinate Tablets Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Frovatriptan Succinate Tablets Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Frovatriptan Succinate Tablets Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Frovatriptan Succinate Tablets Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Frovatriptan Succinate Tablets Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global Frovatriptan Succinate Tablets Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global Frovatriptan Succinate Tablets Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Frovatriptan Succinate Tablets Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Frovatriptan Succinate Tablets Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global Frovatriptan Succinate Tablets Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, (2026-2031) & (K Units)
  • Table 57. Endo International Company Information
  • Table 58. Endo International Introduction and Business Overview
  • Table 59. Endo International Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. Endo International Frovatriptan Succinate Tablets Product Offerings
  • Table 61. Endo International Recent Development
  • Table 62. Menarini Company Information
  • Table 63. Menarini Introduction and Business Overview
  • Table 64. Menarini Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. Menarini Frovatriptan Succinate Tablets Product Offerings
  • Table 66. Menarini Recent Development
  • Table 67. Ingenus Pharmaceutical Company Information
  • Table 68. Ingenus Pharmaceutical Introduction and Business Overview
  • Table 69. Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
  • Table 71. Ingenus Pharmaceutical Recent Development
  • Table 72. Glenmark Pharmaceuticals Company Information
  • Table 73. Glenmark Pharmaceuticals Introduction and Business Overview
  • Table 74. Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
  • Table 76. Glenmark Pharmaceuticals Recent Development
  • Table 77. SK Chemicals Company Information
  • Table 78. SK Chemicals Introduction and Business Overview
  • Table 79. SK Chemicals Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. SK Chemicals Frovatriptan Succinate Tablets Product Offerings
  • Table 81. SK Chemicals Recent Development
  • Table 82. Teva Company Information
  • Table 83. Teva Introduction and Business Overview
  • Table 84. Teva Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 85. Teva Frovatriptan Succinate Tablets Product Offerings
  • Table 86. Teva Recent Development
  • Table 87. G.L. Pharma Company Information
  • Table 88. G.L. Pharma Introduction and Business Overview
  • Table 89. G.L. Pharma Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 90. G.L. Pharma Frovatriptan Succinate Tablets Product Offerings
  • Table 91. G.L. Pharma Recent Development
  • Table 92. Clydesdale Pharma Company Information
  • Table 93. Clydesdale Pharma Introduction and Business Overview
  • Table 94. Clydesdale Pharma Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 95. Clydesdale Pharma Frovatriptan Succinate Tablets Product Offerings
  • Table 96. Clydesdale Pharma Recent Development
  • Table 97. Amneal Pharmaceuticals Company Information
  • Table 98. Amneal Pharmaceuticals Introduction and Business Overview
  • Table 99. Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 100. Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
  • Table 101. Amneal Pharmaceuticals Recent Development
  • Table 102. Renata PLC Company Information
  • Table 103. Renata PLC Introduction and Business Overview
  • Table 104. Renata PLC Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 105. Renata PLC Frovatriptan Succinate Tablets Product Offerings
  • Table 106. Renata PLC Recent Development
  • Table 107. Qingdao Guoxin Pharmaceutical Company Information
  • Table 108. Qingdao Guoxin Pharmaceutical Introduction and Business Overview
  • Table 109. Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 110. Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
  • Table 111. Qingdao Guoxin Pharmaceutical Recent Development
  • Table 112. Key Raw Materials Lists
  • Table 113. Raw Materials Key Suppliers Lists
  • Table 114. Frovatriptan Succinate Tablets Downstream Customers
  • Table 115. Frovatriptan Succinate Tablets Distributors List
  • Table 116. Research Programs/Design for This Report
  • Table 117. Key Data Information from Secondary Sources
  • Table 118. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Frovatriptan Succinate Tablets Product Picture
  • Figure 2. Global Frovatriptan Succinate Tablets Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Frovatriptan Succinate Tablets Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Frovatriptan Succinate Tablets Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Frovatriptan Succinate Tablets Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. Frovatriptan Succinate Tablets Report Years Considered
  • Figure 7. Global Frovatriptan Succinate Tablets Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Frovatriptan Succinate Tablets Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Frovatriptan Succinate Tablets Revenue in 2024
  • Figure 10. Frovatriptan Succinate Tablets Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Original Drug Picture
  • Figure 12. Generic Drug Picture
  • Figure 13. Global Frovatriptan Succinate Tablets Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Frovatriptan Succinate Tablets Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Frovatriptan Succinate Tablets Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 16. Global Frovatriptan Succinate Tablets Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Frovatriptan Succinate Tablets Price by Type (2020-2031) & (US$/Unit)
  • Figure 18. Product Picture of Hospital and Clinic
  • Figure 19. Product Picture of Retail Pharmacies
  • Figure 20. Product Picture of Other
  • Figure 21. Global Frovatriptan Succinate Tablets Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Frovatriptan Succinate Tablets Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Frovatriptan Succinate Tablets Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 24. Global Frovatriptan Succinate Tablets Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Frovatriptan Succinate Tablets Price by Application (2020-2031) & (US$/Unit)
  • Figure 26. North America Frovatriptan Succinate Tablets Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Frovatriptan Succinate Tablets Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume (%), (2020-2031)
  • Figure 38. United States Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Frovatriptan Succinate Tablets Industrial Chain
  • Figure 60. Frovatriptan Succinate Tablets Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed